Data di Pubblicazione:
2016
Citazione:
Pharmacokinetic interactions of monoclonal antibodies / N. Ferri, S. Bellosta, L. Baldessin, D. Boccia, G. Racagni, A. Corsini. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - 111(2016 Sep), pp. 592-599.
Abstract:
The clearance of therapeutic monoclonal antibodies (mAbs) typically does not involve CYP450-mediated metabolism or interaction with cell membrane transporters, therefore the pharmacokinetic interaction of mAbs and small molecule drugs is limited. However, a drug may affect the clearance of mAbs through the modulation of immune response (e.g., methotrexate reduces the clearance of infliximab, adalimumab, and golimumab, possibly due to methotrexate's inhibitory effect on the formation of antibodies against the mAbs). In addition, mAbs that are cytokine modulators may modify the metabolism of drugs through their effects on the regulation pathways of P450 enzymes. For example, cytokine modulators such as tocilizumab (anti-IL-6 receptor antibody) may reverse the "inhibitory" effect of IL-6 on CYP substrates, resulting in a "normalization" of CYP activities. Finally, a drug may alter the clearance of mAbs by either increasing or reducing the levels of expression of targets of mAbs on the cell surface. For instance, statins and fibrates induce PCSK9 expression and therefore increase cellular uptake and clearance of alirocumab and evolocumab, anti-PCSK9 antibodies. In the present review, we will provide an overview on the pharmacokinetics properties of mAbs as related to the most relevant examples of mAbs-small molecule drug interaction.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
IL-6; PCSK9; alirocumab; evolocumab; methotrexate; monoclonal antibodies; reticuloendothelial system; simvastatin; tocilizumab
Elenco autori:
N. Ferri, S. Bellosta, L. Baldessin, D. Boccia, G. Racagni, A. Corsini
Link alla scheda completa: